Health
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV – Press Release – Digital Journal
Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
- Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
- Submission of CVnCoV pre-clinical data package marks start of the rolling process
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 12, 2021 / CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission with the European Medicines Agency (EMA)…
Continue Reading
-
General10 hours agoByford rail extension opening marks final stage of Perth Metronet
-
General22 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
Noosa News16 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General12 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery